TRV-120027,99.46%

产品编号:Bellancom-P2141| CAS NO:1234510-46-3| 分子式:C43H67N13O10| 分子量:926.07

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,

货号 包装 价格 库存与货期 购买量 操作
Bellancom-P2141
750.00 杭州 北京(现货)
Bellancom-P2141
2200.00 杭州 北京(现货)
Bellancom-P2141
3500.00 杭州 北京(现货)

增值税发票√顺丰快递√订货电话:18601927057

TRV-120027

产品介绍 TRV120027 是血管紧张素 II 受体 1 型 (AT1R) 的 β-arrestin-1 激动剂。TRV120027 通过阳离子通道亚家族 C3 (TRPC3) 偶联诱导急性儿茶酚胺分泌,促进质膜上 AT1R-β-arrestin-1-TRPC3-PLCγ形成大分子复合物。TRV120027 抑制血管紧张素 II 介导的血管收缩并增加心肌细胞的收缩力。TRV120027 有潜力用于急性失代偿性心力衰竭 (ADHF) 的研究。
生物活性

TRV120027, a β-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R), engages ß-arrestins while blocking G-protein signaling. TRV120027 induces acute catecholamine secretion through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R–β-arrestin-1–TRPC3–PLCγ at the plasma membrane. TRV120027 inhibits angiotensin II–mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 has the potential for the acute decompensated heart failure (ADHF) treatment.

体外研究

TRV120027 (100 nM) significantly increases the AT1R and TRPC3 association with the immunoprecipitated β-arrestin-1 in HEK293 cells co-transfected with Flag-AT1R-cherry, HA-β-arrestin-1 and TRPC3-GFP.
TRV120027 (100 nM) induces an [Ca2+]i increase in HEK293 cells co-transfected with AT1R, β-arrestin-1, and TRPC3, which are significantly blocked by Pyr3 pre-incubation in HEK293 cells co-transfected with Flag-AT1R-Cherry, HA-β-arrestin-1, and TRPC3-GFP.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

TRV120027 (intravenous injection; 0.3 or 1.5 µg/kg per minute; infusion rate, 0.5 mL/min) when added to furosemide decreases cardiac preload and afterload, systemic and renal vascular resistances, and left ventricular external work while increasing cardiac output and renal blood flow. GFR and renal excretory function are maintained in canines with experimental HF.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male mongrel dogs (weight, 20.5–30 kg)
Dosage: 0.3 or 1.5 µg/kg per minute; infusion rate, 0.5 mL/min
Administration: Intravenous injection
Result: Resulted in dose-dependent vasodilation, increased cardiac contractility, and decreased myocardial oxygen consumption in dog.
体内研究

TRV120027 (intravenous injection; 0.3 or 1.5 µg/kg per minute; infusion rate, 0.5 mL/min) when added to furosemide decreases cardiac preload and afterload, systemic and renal vascular resistances, and left ventricular external work while increasing cardiac output and renal blood flow. GFR and renal excretory function are maintained in canines with experimental HF.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male mongrel dogs (weight, 20.5–30 kg)
Dosage: 0.3 or 1.5 µg/kg per minute; infusion rate, 0.5 mL/min
Administration: Intravenous injection
Result: Resulted in dose-dependent vasodilation, increased cardiac contractility, and decreased myocardial oxygen consumption in dog.
性状Solid
溶解性数据
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture and light, under nitrogen

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)

参考文献

相关文档

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

相关产品


服务热线

13911702513
18601927057

微信客服